Donna Hagberg
Cos Cob, CTNPI 1578691465
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,954 of the $2,180 with a category attached, or 89.6%. It is spread thinly across 18 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations.
Across 87 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$373
- Millicent US Inc$320
- Mayne Pharma Commercial LLC$301
- Astellas Pharma US Inc$258
- Therapeuticsmd, Inc.$193
- Evofem Biosciences, Inc.$117
- plus $619 from 12 others
What the payments were for
- Food & beverage$1,95490%
- Education$22610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $373 |
| Millicent US Inc | 7 | $320 |
| Mayne Pharma Commercial LLC | 12 | $301 |
| Astellas Pharma US Inc | 6 | $258 |
| Therapeuticsmd, Inc. | 9 | $193 |
| Evofem Biosciences, Inc. | 6 | $117 |
| Pfizer | 5 | $113 |
| Exact Sciences | 4 | $108 |
| Bayer | 4 | $70 |
| Sumitomo Pharma America, Inc. | 3 | $65 |
| Scynexis, Inc. | 2 | $54 |
| Avion Pharmaceuticals | 3 | $47 |
| Coopersurgical, Inc. | 2 | $43 |
| Hologic Sales And Service, LLC | 2 | $38 |
| Ascend Therapeutics US, LLC | 2 | $24 |
| GSK | 1 | $20 |
| AMAG Pharmaceuticals, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$124
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 150 | $16,723 |
| PremarinEstrogens, Conjugated | 31 | $13,537 |
| EstringEstradiol | 21 | $11,005 |
| YuvafemEstradiol | 40 | $5,896 |
| Estradiol (Twice Weekly)Estradiol | 46 | $4,929 |
| DottiEstradiol | 17 | $2,644 |
| ProgesteroneProgesterone, Micronized | 57 | $1,530 |
| ValacyclovirValacyclovir Hcl | 53 | $1,016 |
| Clobetasol Propionate | 17 | $372 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $153 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $144 |
| Fluconazole | 12 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin, Estring | $113 | $24,54152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.